Localized Amyloidosis at the Site of Enfuvirtide Injection
Authors: Miguel Emilio Morilla, Jeffrey Kocher, Marco Harmaty
Journal: Annals of Internal Medicine (2009)

Letters6 October 2009Localized Amyloidosis at the Site of Enfuvirtide InjectionMiguel Emilio Morilla, MD, Jeffrey Kocher, MD, and Marco Harmaty, MDMiguel Emilio Morilla, MDFrom Mount Sinai School of Medicine, Englewood Hospital Program, Englewood, NJ 07631; Englewood Hospital, Englewood, NJ 07631; and Mount Sinai School of Medicine, New York, NY 10029., Jeffrey Kocher, MDFrom Mount Sinai School of Medicine, Englewood Hospital Program, Englewood, NJ 07631; Englewood Hospital, Englewood, NJ 07631; and Mount Sinai School of Medicine, New York, NY 10029., and Marco Harmaty, MDFrom Mount Sinai School of Medicine, Englewood Hospital Program, Englewood, NJ 07631; Englewood Hospital, Englewood, NJ 07631; and Mount Sinai School of Medicine, New York, NY 10029.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-7-200910060-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Enfuvirtide is the first of a new class of antiretroviral agents that block fusion of the viral particle with the host target cell. Its safety and antiviral activity have been demonstrated (1, 2). In clinical trials, injection site reactions occurred in 80% to 100% of patients (3). The most common signs and symptoms reported were induration in 94%, erythema in 91%, and subcutaneous nodules and cysts in 70% (4).Objective: To describe a case of amyloidosis at the injection site of enfuvirtide.Case Report: The patient was a man aged 47 years who had a history of sexual intercourse ...References1. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-85. [PMID: 12637625] CrossrefMedlineGoogle Scholar2. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, et al; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2004;23:713-8. [PMID: 15295220] CrossrefMedlineGoogle Scholar3. Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, et al. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antivir Ther. 2006;11:935-9. [PMID: 17302257] MedlineGoogle Scholar4. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-95. [PMID: 12773645] CrossrefMedlineGoogle Scholar5. Ball RA, Kinchelow T; ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003;49:826-31. [PMID: 14576660] CrossrefMedlineGoogle Scholar6. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53:678-81. [PMID: 14985276] CrossrefMedlineGoogle Scholar7. Steciuk A, Dompmartin A, Troussard X, Verneuil L, Macro M, Comoz F, et al. Cutaneous amyloidosis and possible association with systemic amyloidosis. Int J Dermatol. 2002;41:127-32; discussion 133-4. [PMID: 12010335] Google Scholar8. Nguyen TU, Oghalai JS, McGregor DK, Janssen NM, Huston DP. Subcutaneous nodular amyloidosis: a case report and review of the literature. Hum Pathol. 2001;32:346-8. [PMID: 11274647] CrossrefMedlineGoogle Scholar9. Love WE, Miedler JD, Smith MK, Mostow EN, Cooper KD, Gilliam AC. The spectrum of primary cutaneous nodular amyloidosis: Two illustrative cases [Letter]. J Am Acad Dermatol. 2008;58:S33-5. [PMID: 18191697] CrossrefMedlineGoogle Scholar10. Störkel S, Schneider HM, Müntefering H, Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest. 1983;48:108-11. [PMID: 6337294] MedlineGoogle Scholar11. Swift B. Examination of insulin injection sites: an unexpected finding of localized amyloidosis [Letter]. Diabet Med. 2002;19:881-2. [PMID: 12358880] CrossrefMedlineGoogle Scholar12. Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Rennie JA, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia. 1988;31:158-61. [PMID: 3286343] CrossrefMedlineGoogle Scholar13. Ciin LC, Barker D, Tymms DJ. Unexpected finding of amyloidosis at the site of insulin injection. Pract Diab Int. 2005;22:118. CrossrefGoogle Scholar14. Wei BP, Somers GR, Castles L. Dystrophic calcification and amyloidosis in old subcutaneous injection sites. ANZ J Surg. 2003;73:556-8. [PMID: 12864841] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Miguel Emilio Morilla, MD; Jeffrey Kocher, MD; Marco Harmaty, MDAffiliations: From Mount Sinai School of Medicine, Englewood Hospital Program, Englewood, NJ 07631; Englewood Hospital, Englewood, NJ 07631; and Mount Sinai School of Medicine, New York, NY 10029.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAmyloidogenicity of peptides targeting diabetes and obesityTreating Protein Misfolding Diseases: Therapeutic Successes Against Systemic AmyloidosesAmyloidosis: Insights from ProteomicsEnfuvirtideIatrogenic Pharmaceutical Amyloidosis Associated with Insulin and Enfuvirtide AdministrationPharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administrationEnfuvirtide injection site reactions: A clinical and histopathological appraisalAntiviral drugsNodular amyloidosis in a diabetic patient with frequent hypoglycemia: Sequelae of repeatedly injecting insulin without site rotation 6 October 2009Volume 151, Issue 7Page: 515-516KeywordsAmyloidosisAntiretroviralsDrugsHemorrhageHIVLesionsStainingSubcutaneous injectionsUlcersViral load ePublished: 6 October 2009 Issue Published: 6 October 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...